telomere: one bounded, context-dependent signal across receipts

Source literature boundary memo

Research question

Across retrieved fact-level receipts for telomere, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

Selection criteria

The source-literature fallback selected telomere because the domain snapshot exposed enough fact-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Boundary map

• Does oxidative stress shorten telomeres in vivo? A meta-analysis [review; 2023] doi:10.1016/j.arr.2023.101854
  • Finding: This revealed a significant effect of treatment on telomere dynamics (d=0.36).
  • Population: interventional studies manipulating oxidative stress
  • Intervention/exposure: oxidative stress manipulation (treatment)
  • Comparator: control
• Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population [primary; 2021] doi:10.1002/hep4.1803
  • Finding: The liver disease cohort (HR 1.22, 95% CI 0.99-1.51) had increased mortality risk with shorter TL
  • Population: liver disease cohort
  • Intervention/exposure: telomere length
  • Comparator: shorter vs longer TL
• Telomere length and aging‐related outcomes in humans: A Mendelian randomization study in 261,000 older participants [primary; 2019] doi:10.1111/acel.13017
  • Finding: but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16)
  • Population: UK Biobank participants aged 60 and older
  • Intervention/exposure: genetically determined longer telomere length (per 250 base pairs increase)
  • Comparator: shorter telomere length
• The Association of Telomere Length in Peripheral Blood Cells with Cancer Risk: A Systematic Review and Meta-analysis of Prospective Studies [review; 2017] doi:10.1158/1055-9965.epi-16-0968
  • Finding: In the comparison of the longest versus shortest third of TL, we observed a marginally positive association between longer TL and higher risk of total cancers [OR = 1.086; 95% CI, 0.952-1.238].
  • Population: 13,894 cases and 71,672 controls from 28 studies in 25 articles
  • Intervention/exposure: longest third of telomere length vs shortest third
  • Comparator: shortest third of telomere length
• Short telomere length is associated with impaired cognitive performance in European ancestry cohorts [primary; 2017] doi:10.1038/tp.2017.73
  • Finding: longer telomeres were associated with better scores on DSST (β=0.051 per s.d.-increase of TL; 95% CI: 0.024, 0.077; P=0.0002)
  • Population: European ancestry cohorts (N=17,052; mean age=59.2±8.8 years)
  • Intervention/exposure: longer telomere length (per s.d.-increase of TL)
  • Comparator: shorter telomere length

Source synthesis

This receipt-backed scoping note has one bounded signal: telomere shows context-dependent, not uniformly convergent associations across this 5-source primary/review bundle (2017-2023). Grouped by direction, directionally favorable: 1 receipt(s) | other/mixed: 4 receipt(s). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: This revealed a significant effect of treatment on telomere dynamics (d=0.36); The liver disease cohort (HR 1.22, 95% CI 0.99-1.51) had increased mortality risk with shorter TL; but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16).

Directional grouping

• directionally favorable: telomere is the intervention/exposure and the reported clinical endpoint favors that arm.

• comparator/not favorable: telomere is the comparator arm; the label is limited to that head-to-head endpoint.

• economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.

• null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

• other/mixed: Does oxidative stress shorten telomeres in vivo? A meta-analysis — This revealed a significant effect of treatment on telomere dynamics (d=0.36).

• other/mixed: Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population — The liver disease cohort (HR 1.22, 95% CI 0.99-1.51) had increased mortality risk with shorter TL

• other/mixed: Telomere length and aging‐related outcomes in humans: A Mendelian randomization study in 261,000 older participants — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16)

• other/mixed: The Association of Telomere Length in Peripheral Blood Cells with Cancer Risk: A Systematic Review and Meta-analysis of Prospective Studies — In the comparison of the longest versus shortest third of TL, we observed a marginally positive association between longer TL and higher risk of total cancers [OR = 1.086; 95% CI, 0.952-1.238].

• directionally favorable: Short telomere length is associated with impaired cognitive performance in European ancestry cohorts — longer telomeres were associated with better scores on DSST (β=0.051 per s.d.-increase of TL; 95% CI: 0.024, 0.077; P=0.0002)

Specific moderators in this bundle are population/indication (13,894 cases and 71,672 controls from 28 studies in 25 articles; European ancestry cohorts (N=17,052; mean age=59.2±8.8 years); UK Biobank participants aged 60 and older; interventional studies manipulating oxidative stress; liver disease cohort), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.

Context separation

The selected receipts group because each carries a fact-level extraction for telomere; they separate by context (human clinical/observational and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim.

Boundary limits

Source-literature boundary for telomere: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate. Routing domain longevity_research is publication-lane metadata only; the source scope here is defined by the selected telomere receipts.

Next gaps

A stronger memo needs one matched PICO, for example: population=interventional studies manipulating oxidative stress; intervention/exposure=oxidative stress manipulation (treatment); comparator=control; outcome=one named clinical endpoint. If telomere is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing human clinical/observational and other source context.